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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).SUMMARYThere is no consensus in the stem cell field as to what constitutes themature cardiacmyocyte. Thus, helping formalize amolecular signa-
ture for cardiac myocyte maturation would advance the field. In the mammalian heart, inactivation of the ‘‘fetal’’ TNNI gene, TNNI1
(ssTnI), together in temporal concert with its stoichiometric replacement by the adult TNNI gene product, TNNI3 (cTnI), represents a
quantifiable ratiometric maturation signature. We examined the TNNI isoform transition in human induced pluripotent stem cell
(iPSC) cardiac myocytes (hiPSC-CMs) and found the fetal TNNI signature, even during long-term culture. Rodent stem cell-derived
and primary myocytes, however, transitioned to the adult TnI profile. Acute genetic engineering of hiPSC-CMs enabled a rapid conver-
sion toward the mature TnI profile. While there is no single marker to denote the mature cardiac myocyte, we propose that tracking the
cTnI:ssTnI protein isoform ratio provides a valuable maturation signature to quantify myocyte maturation status across laboratories.INTRODUCTION
Cardiac myocytes derived from progenitors or from so-
matic cell reprogramming are attractive platforms for dis-
ease-modeling studies and have potential in regenerative
medicine. One of the major challenges hindering full real-
ization of stem cell-derived myocytes in the lab and clinic
relates to uncertainties in the maturation status of the my-
ocytes (Ieda et al., 2010; Hansson and Chien, 2012; Qian
et al., 2012; Shiba et al., 2012). The well-characterized car-
diac myocyte developmental profile in vivo can become
disordered when myocytes are isolated and cultured
in vitro. This developmental conundrum presents major
challenges to tracking and documenting the maturation
of stem cell-derived cardiacmyocytes. Tracking thematura-
tion status of human induced pluripotent stem cell-derived
cardiac myocytes (hiPSC-CMs), for example, would be
indispensable in ultimately using these cells as a platform
for in vitro drug discovery or for potential therapeutic ap-
plications in vivo (Hansson and Chien, 2012; Palpant
and Murry, 2012; Shiba et al., 2012).
To date, there is no clear agreement in the stem cell field
as towhat constitutes themature cardiacmyocyte or which
specific marker, if any, can accurately track the differentia-
tion status of stem cell-derived myocytes. For instance,
when primary cardiac myocytes are isolated and cultured
in vitro, they can re-express a myriad of embryonic/fetal
protein isoforms. Further, other well-used structural or
physiological markers, including Ca2+ handling, cell
morphology/striation pattern, and beating, are also limited
by developmental reversion under stress conditions and594 Stem Cell Reports j Vol. 3 j 594–605 j October 14, 2014 j ª2014 The Athus difficult to quantify as strict maturation markers.
Collectively, these issues present challenges to investiga-
tors wishing to track the differentiation status of stem
cell-derived cardiac myocytes. In this light, implementa-
tion of a quantifiable molecular signature for tracking the
differentiation status of cardiac myocytes would advance
the field.
We propose that a quantitative marker for tracking car-
diac myocyte maturation resides in the developmentally
controlled and irreversible (excepting targeted reprogram-
ming) genetic switch in the sarcomeric TNNI gene. Owing
to strict developmental control in all mammalian hearts,
including humans, the programmed inactivation of the
‘‘fetal’’ TNNI gene, TNNI1, together in exquisite temporal
concert with stoichiometric replacement by the adult
gene, TNNI3, represents a unique molecular signature of
the mature adult cardiac myocyte in vivo (Bhavsar et al.,
1991; Sasse et al., 1993; Siedner et al., 2003). The troponin
complex is composed of three subunits—troponin T (TnT),
the tropomyosin binding subunit; troponin C (TnC), the
calcium binding subunit; and troponin I (TnI), an inhibi-
tory subunit (Dhoot et al., 1978; Ohtsuki et al., 1986; Par-
macek and Solaro, 2004)—and controls the interaction of
thick and thin filaments in response to alterations in intra-
cellular Ca2+ concentrations (Ebashi, 1983, 1988; Lehman
et al., 2001; Metzger and Westfall, 2004). The TnT subunit
has been used extensively in attempt to identify the cardiac
lineage (Chan et al., 2013b; Hazeltine et al., 2013; Kawa-
mura et al., 2013; Park et al., 2014; Rebuzzini et al.,
2013). However, cTnT is also expressed in noncardiac cells
such as smooth muscle cells (Porrello et al., 2011, 2013; Luuthors
Figure 1. Temporal Expression Pattern of
TNNI Protein Isoform Content in Rodent
CMs
(A) Schematic of TNNI isoform switching
time course during development of the
mammalian heart.
(B and C) Western blot (B) and summary bar
graph (C) of ventricles of mouse pups at
postnatal days P1–P20. Ventricle from adult
mouse is used as a control.
(D and E) Western blot (D) and summary
bar graph (E) for TnI isoform content in
M-NVCM cultured in vitro for D1–D20.
(F and G) Western blot (F) and summary bar
graph (G) for R-NVCM cultured in vitro for
D1–D20.
(H and I) Western blot (H) and summary bar
graph (I) for Mesp1-mESC-CMs cultured
in vitro for D1–D20.
See also Figures S1–S3. Data analyzed by
two-way ANOVA with Bonferroni post hoc
test and expressed as mean ± SEM, n = 3
independent experiments, p < 0.05 for (C),
(E), (G), and (I).
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et al., 2013), limiting its use as a cardiac lineage marker.
Many other structural, regulatory, morphological, and
metabolic markers have been used for cardiac lineage and
maturation assignment; however, these are subject to
reversion to the fetal program in stress and disease. For
example, the MyH6 gene is highly cardiac specific, but a
transition in myosin isoform content in disease compli-
cates its use for lineage or maturation assignment (Sasse
et al., 1993; Nakao et al., 1997; Reiser et al., 2001)
There are two isoforms of TnI in heart muscle, encoded
on two separate genes that are expressed under strict devel-
opmental control in themammalian heart (Hunkeler et al.,
1991; MacGeoch et al., 1991; Metzger and Westfall, 2004).
The TNNI1 gene (slow skeletal TnI/ssTnI/cardiac fetal) isStem Cellexpressed in the sarcomeres of the fetal heart and in late
fetal/early neonatal life and then fully extinguished such
that there is no ssTnI protein detected in the adult myocar-
dium (Bhavsar et al., 1991; Sasse et al., 1993; Siedner et al.,
2003) (Figure 1A). The TNNI3 gene (adult cardiac TnI/cTnI)
is activated in fetal/early neonatal life and then is ex-
clusively expressed in the adult myocardium. This strict
1:1 conversion is ideal for a differentiation status marker
owing to tight preservation of sarcomere stoichiometry
throughout development. This differs, for example, from
tracking a marker that increases in maturation because
the critical internal control of a reference ‘‘fetal’’ marker
decreasing in parallel is lacking. Further, the ssTnI (fetal)
to cTnI (adult) isoform stoichiometric conversion does
not revert to the ‘‘fetal’’ gene program in cardiac stress orReports j Vol. 3 j 594–605 j October 14, 2014 j ª2014 The Authors 595
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Huang et al., 2000), in distinction with reversible differen-
tiation status markers currently in use (Razeghi et al., 2001;
Lundy et al., 2013). The combined properties of stoichio-
metric conservation and general irreversibility are unique
in combination and make the cTnI: ssTnI protein isoform
ratio potentially highly useful as a quantitative marker of
maturation status.
Using this marker of maturation, our findings show that
rodent neonatal and murine embryonic stem cell (ESC)-
derived cardiac myocytes in culture track the transition in
the ssTnI to cTnI protein isoform switch comparable to
the temporal pattern in vivo. In comparison, hiPSC-CMs
beating continuously in culture retain a fetal-like state in
terms of the TnI isoformprofile regardless of differentiation
condition, hiPSC line (five different hiPSC-CMs lines
tested), and duration of culture (9+ months). By instituting
a maturation status marker, as proposed here, myocytes
derived from any progenitor/reprogramming approach
and with any differentiation protocol can be directly and
quantitatively compared across laboratories.
While the TnI isoform ratio is proposed here to be neces-
sary for tracking maturation of stem cell-derived cardiac
myocyte, it is not sufficient, on its own, to establish the
mature adult cardiac myocyte state. Thus, we suggest that
the TnI protein isoform profile be instituted as one in-
dispensible component to be added to the myriad of ma-
turation markers, including functional, morphological,
metabolic and structural markers, required for the assign-
ment of the mature adult cardiac myocyte state.RESULTS
Temporal Pattern of ssTnI to cTnI Isoform Switching
in Rodent-CMs In Vivo and In Vitro
To validate the TnI molecular signature of maturation in
CMs, first we assessed the natural temporal developmental
transition of ssTnI to cTnI in rodents in vivo. We isolated
protein and RNA from ventricles of postnatal mouse pups
at specific postnatal time points (days), postnatal day 1
(P1) to P20. Western blots determined greater than 90%
cTnI expression with concomitant stoichiometrically
conserved reduction of ssTnI protein in vivo at day 20 (Fig-
ures 1B and 1C). We observed a similar developmental
transition pattern at the mRNA level (Figures S2A and
S2B available online). Following the validation of TnI iso-
form maturation profile in vivo, we set out to assess the
TNNI developmental expression pattern in vitro. Protein
samples were collected at time points 1, 3, 5, 7, 10, 15,
and 20 days after isolation and plating in culture and
were analyzed for ssTnI and cTnI content. Western blots
showed cTnI expression in cultured mouse neonatal car-596 Stem Cell Reports j Vol. 3 j 594–605 j October 14, 2014 j ª2014 The Adiac myocytes that increased over time and with ssTnI
expression stoichiometrically reduced in temporal concert
with the increased cTnI expression (Figures 1D and 1E).
This same general pattern was obtained in rat neonatal car-
diac myocytes and inmouseMesp-1 ESC-derived CMs (Fig-
ures 1F–1I). We also performed immunohistochemistry
and found appropriate sarcomeric localization of cTnI
in the rodent-CMs (Figures S3D and S3G). Additionally,
in each case (neonatal or Mesp-1), CMs in the biological
matrix aligned and displayed enhanced sarcomere organi-
zation (Figures S3J–S3M). However, refined sarcomeric
organization and myocyte alignment did not affect the
timing of the ssTnI:cTnI isoform conversion (Figures S3D
and S3G).
Temporal Pattern of ssTnI to cTnI Switch in
hiPSC-CMs
To gain insight into the molecular signature of cardiac my-
ocyte maturation, hiPSC-CMs were studied in biological
cardiac matrix with continuous spontaneous beating
from 1 week to 9.5 months in vitro (Figure 2). To analyze
the TNNI isoform expression pattern, protein samples
were collected at time points 1, 2, 3, 4, 5, 6, and 7 weeks
and 2, 6, and 9.5 months and ssTnI to cTnI (TNNI iso-
forms) content determined. Figure 2 documents the
pattern of transition from TNNI1 (ssTnI) to TNNI3 (cTnI)
by western blot. Protein samples from adult human hearts
were used as a positive control. Western blot data showed
that ssTnI isoform content was dominant with no evi-
dence of significant diminution even after culture for
9.5 months (Figures 2A and 2B). The hiPSC-CMs did ex-
press limited yet detectable amount of cTnI after 2 months
of culture; however, this level did not change even up to
9.5 months of culture, the longest period studied. Western
blot-based quantification showed only 2% of total TnI con-
tent was the cTnI isoform at the end of the study period
(9.5 months of culture) and is evidence of stalled develop-
mental maturation. In these experiments, to address issues
of noncardiac growth during long-term culture, we used
the RPMI and B27+ insulin cocktail that does not promote
fibroblast outgrowth compared with culturing in fetal
bovine serum (FBS).
Immunofluorescence (IF) showed sarcomere detection of
cTnI in hiPSC-CMs (Figure S3A); however, when compared
with the western blot data, this finding underscores the
challenges of using IF to quantify this maturation marker.
Structurally, as found in neonatal rodent and Mesp1-
mESC derived CMs, hiPSC-CMs cultured on biological
matrix aligned and displayed enhanced sarcomere organi-
zation compared to controls cultured usingMatrigel-coated
plates (Figure 2D). Whereas biological matrix (Figure 2C)
facilitated sarcomere alignment in hiPSC-CMs, it did not
affect the relative TNNI isoform profile during culture.uthors
Figure 2. Temporal Expression Pattern of TNNI Protein Isoform
Content and Sarcomeric Alignment of hiPSC-CMs by Biological
Matrix
(A) Western blot data using pan TnI antibody showing dominant
expression of ssTnI and little detectable cTnI expression even after
culture of hiPSC-CMs spontaneously beating for 9.5 months. Adult
human ventricular sample was used as positive control (far right
lane).
(B) Summary bar graph of TnI isoform content in hiPSC-CMs
during long-term culture in vitro (taken from western data in
part A).
(C) Images of rat cardiac thin slice matrix constructs showing
decellularization stages of transverse cardiac matrix isolated from
whole heart. The whole heart was placed in stainless steel rat heart
slicer and cut at 1 mm per thin slice before 1% SDS treatment (I)
and 1 hr (II), 2 hr (III), 4 hr (IV), 24 hr (V), and 72 hr (VI) after 1%
SDS treatment. Scale bar is 2 mm.
(D) Structural organization of hiPSC-CMs during culture with
and without biological matrix. The images were taken with 403
objective; the calibration bar is 50 mm.
See also Figures S1, S3, and S4.
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in Different hiPSC-CMs Lines
The stalled TnI isoform developmental transition we
observed could have been specific to the DF19-9-11
hiPSC line or the differentiation protocol used. To address
these possibilities, we performed companion studies using
hiPSC-CMs obtained from multiple labs (see Experimental
Procedures) and using different differentiation protocols.
RNA and protein were extracted from five hiPSC-CMs
lines at specific temporal points, including day 10,
2 weeks, 1 month, day 80, and 3 and 5 months. Whereas
western blot analysis showed some cTnI induction
in these additional lines, the stoichiometric ratio of
cTnI:ssTnI remained very low and indicative of the imma-
ture state (Figure 3), similar to the DF19-9-11 hiPSC line
(Figure 2).
Accelerated Acquisition of the Mature TnI Signature
by T3 Supplementation in Rodent CMs, but Not
hiPSC-CMs
The fetal gene program is regulated in response to develop-
mental, hormonal, and hemodynamic stimuli (Parker
et al., 1990). Thyroid hormone is critical in heart matura-
tion during development (Chang et al., 1997; Trivieri
et al., 2006; Mourouzis et al., 2011). Thus, we tested the
direct effect of T3 on the TNNI isoform switch in hiPSC-
CMs by supplementing media with 10 nM triiodothyro-
nine (T3) for 2 weeks starting at 2 months postbeating of
hiPSC-CMs (Figure 4). The 2 months postbeating time
point was used for hiPSC-CMs because cTnI expression at
this time point is comparable to cTnI expression profile at
day 1 of rodent CMs (Figures 1D, 1F, and 1H). In parallel
studies, hiPSC-CM media was supplemented with T3 at
the onset of beating to compare to rodent CMs (Figure 4A).
For comparison, day 1 Mesp1-mESC-CMs, M-NVCMs, and
R-NVCMs (see Experimental Procedures) were supple-
mented with T3 for 2 weeks. Western blots showed
the TnI isoform profile in hiPSC-CMs was not affected by
T3 treatment (Figure 4), whereas Mesp1-mESC-CMs and
rodentNVCMs responded significantly to T3 supplementa-
tion with Mesp1-mESC-CM expressing 95% and M-NVCM
98% cTnI post-T3 (Figures 4B–4D).
Acquisition of the Mature Signature by Stoichiometric
Gene Replacement
Because hiPSC-CMs had stalled acquisition of the mature
molecular signature, we sought to augment hiPSC-CM
with exogenous adenoviral mediated gene transfer of
human cTnI (Figure 5A). To test for acute expression of
human cTnI on hiPSC-CMs, we generated adenovirus ex-
pressing cTnI and transduced hiPSC-CMs in serum-free pri-
mary culture conditions and assessed the expression of
cTnI by western blotting. Post-cTnI gene transduction,Reports j Vol. 3 j 594–605 j October 14, 2014 j ª2014 The Authors 597
Figure 3. Temporal Expression Pattern of TNNI Isoform mRNA
and Protein in Different hiPSC-CMs Lines
(A–C) The temporal developmental transition of ssTnI to cTnI was
analyzed at the mRNA level to evaluate the transcriptional regu-
lation in vitro in five hiPSC-CMs lines (A and B). RNA samples were
prepared from five hiPSC-CMs lines obtained from different labs
employing different differentiation conditions. The analyzed tem-
poral points include day 10, 2 weeks, 1 month, day 80, and 3 and
5 months. A ventricle from an adult heart was used as a control.
Quantitative RT-PCR data shows slight increase in the level of cTnI
and concomitant reduction in ssTnI for hiPSC-CMs cultured for day
80 and 3 and 5 months in vitro (A and B). Data shown are expressed
from average of (two) biological replicates. Western blot data using
a pan TnI antibody showing the dominant expression of ssTnI and
small yet detectable cTnI expression after culture of hiPSC-CMs for
day 80 and 3 and 5 months in vitro (C).
(D) Summary of TnI isoform content in hiPSC-CMs obtained from
different lines (taken from western data in part C). cTnC is used as
598 Stem Cell Reports j Vol. 3 j 594–605 j October 14, 2014 j ª2014 The A
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undetected cTnI content in nontransduced hiPSC-CMs
(Figures 5B–5D). The level of ssTnI in cTnI transduced
hiPSC-CMs was correspondingly reduced, consistent with
stoichiometric sarcomere replacement. To assess if the
observed effect is species dependent, we also transduced
R-NVCM with a similar protocol used for hiPSC-CMs
(Figure S5A). We observed 85% expression of cTnI 7 days
posttransduction of R-NVCM compared to nontransduced
controls (Figure S5B and S5C). The level of ssTnI was also
significantly reduced compared with the nontransduced
control (Figures S5B and S5D).
Acquisition of Chamber-Specific Markers in
hiPSC-CMs
We used myosin light chain (MLC) 2a and 2v, atrial and
ventricular chamber markers, respectively, to further track
the identity and assess the TNNI isoform maturation gene
switch in hiPSC-CMs. We employed IF to localize the
expression of MLC2a and MLC2v at 20 and 60 days post-
continuous spontaneous beating of hiPSC-CMs. At day
20, very few hiPSC-CMs were positive by IF for MLC2v as
the vast majority of hiPSC-CM expressed MLC2a (Figures
S4A–S4C). Interestingly, by day 60, MLC2v expression
was robust while MLC2a expression was decreased (Figures
S4D–S4F). Next, we used IF to evaluate whether MLC2v
(ventricular marker) and cTnI (mature marker) were colo-
calized in 60 days post-spontaneous beating hiPSC-CM.
Immunofluorescence and laser confocal scanning analysis
demonstrated that hiPSC-CMs express primarily MLC2v
with sparse cTnI detection (Figure S3). In day 20 rodent
CMs, cTnI exclusively colocalized with MLC2v (Figure S3).
For day 20 Mesp1-mESC-CMs, cTnI colocalized with
MLC2v, suggesting mature ventricular cells with some
cTnI-expressing myocytes that did not colocalize with
MLC2v, suggesting these are atrial mature myocytes (Fig-
ure S3). These data also underscore the limitation of using
IF as a mechanism to document TNNI isoform switching as
compared to the quantification possible by western blot-
ting (Figures 1, 2, 3, 4, and 5).DISCUSSION
There is tremendous interest and many recent advances in
the dynamic field of cardiac stem cell biology. Major break-
throughs in iPSC and reprogramming technologies further
enable the potential of stem cell-based therapeutics in heart
disease (Takahashi et al., 2007; Ieda et al., 2010). Beforecardiac-specific loading control and for normalization of samples
for quantification purposes. Data shown are expressed from average
of (two) biological replicates.
uthors
Figure 4. Accelerated Acquisition of the Mature TNNI Isoform
Signature by T3 Supplementation in Rodent CMs, but Not in
hiPSC-CMs
(A) Schematic of experimental time line for T3 supplementation in
hiPSC-CM and rodent CMs. Two experimental time lines were used
for hiPSC-CMs. The first was at 2 months postinitiation of beating,
and the second time point was shortly after initiation of beating.
(B) Representative western blots TnI isoform profile detection after
T3 supplementation (10 nM of T3 for 2 weeks in culture of 2 months
beating hiPSC-CMs or early time point [1–2 days beating hiPSC-
CMs] or 1 day rodent CMs).
(C and D) The effect of T3 treatment (T3+) or its absence (T3) on
acquisition of cTnI is quantified in (C) and suppression of ssTnI is
quantified in (D). cTnC is used as cardiac-specific loading control and
for normalization. Data analyzed by two-tailed t test and expressed
as mean ± SEM, n = 3 independent experiments per group, *p < 0.05.
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remain, including cell lineage assignment and maturation
status of the myocytes. A general consensus in the field isStem Cellthat stem cell-derived myocytes are immature; however,
there are no widely accepted markers to define and track
the precise differentiation status of the emergingmyocytes.
Accordingly, the field would be advanced by establishing a
molecular signature for tracking the differentiation status
of stem cell-derived cardiac myocytes. In this light, we pro-
pose that the developmentally controlled and irreversible
genetic switch in the sarcomeric TNNI genes provides an
excellent marker to track the differentiation status of stem
cell-derived cardiac myocytes. Owing to strict develop-
mental control in all mammalian hearts, including hu-
mans, the programmed inactivation of the ‘‘fetal’’ TNNI
gene product, ssTnI, together in exquisite temporal concert
with stoichiometric replacement by the adult gene product,
cTnI, represents a unique molecular marker of cardiac my-
ocyte maturation status (Bhavsar et al., 1991).
Tracking the maturation status of stem cell-derived car-
diacmyocytes by ratiometric analysis of the cTnI:ssTnI pro-
tein profile provides a tool to permit direct comparisons of
myocyte developmental status from different cell lines and
with using different culture methods and differentiation
protocol across laboratories. Tracking the cTnI/ssTnI iso-
form expression profilewill be useful in cataloging the large
array of other pertinent markers of myocyte development
including molecular, structural, electrical, morphological,
and functional features of maturing stem cell-derived car-
diac myocytes. Ultimately, to be defined as an adult myo-
cyte would require acquisition of thewell-known structural
and functional profile of the mature myocyte, and we pro-
pose the adult designation would require the exclusive
expression of the cTnI isoform (Bhavsar et al., 1991; Sied-
ner et al., 2003).
Key features of the TnI protein isoform switch as a quan-
titative standard for cardiac stem cell-derived myocyte
maturation are (1) its stoichiometric conservation, (2) its
normal developmental irreversibility, and (3) its physiolog-
ical significance (Siedner et al., 2003; Davis et al., 2008).
Conservation of a strict one-to-one stoichiometric expres-
sion pattern provides a unique internal standard on which
the cTnI:ssTnI isoform ratio informs a direct quantitative
marker of development. This differs from tracking, for
example, the relative abundance of a single cardiac marker
in developing cells, such as cardiac actin, a-actinin, or
myosin light chains, because a reference internal ‘‘fetal’’
standard is lacking thus limiting their use. Further, often
used cardiac developmentmarkers such as cellmorphology
and striation appearance are inherently subjective in terms
of precise tracking and cataloging maturation progression.
Irreversibility in the ssTnI to cTnI transition is of value as a
maturationmarker. At the level of the cardiac sarcomere, as
cTnI (TNNI3 gene product) progressively replaces ssTnI
(TNNI1) during maturation, there is no reactivation of
the fetal TNNI1 gene program, even in disease statesReports j Vol. 3 j 594–605 j October 14, 2014 j ª2014 The Authors 599
Figure 5. Acquisition of the Mature TNNI Isoform Signature by
Gene Transfer in hiPSC-CMs
(A) Experimental time line for AdcTnI (flag tagged) gene transfer.
(B–D) Western blot probed with pan TnI isoform antibody (B) and
summary bar graphs of relative cTnI expression (C) and ssTnI
600 Stem Cell Reports j Vol. 3 j 594–605 j October 14, 2014 j ª2014 The A
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tive), ischemia, or in heart failure (Bhavsar et al., 1991; So-
laro, 1999). In all mammalian hearts, including human, it
is the complete stoichiometric replacement of ssTnI by
cTnI that is as an immutable profile of acquiring themature
adult state. Accordingly, to be termed adult, a cardiac myo-
cyte requires a profile of 100% cTnI and 0% (i.e., undetect-
able) ssTnI. It would be insufficient, for example, to simply
detect cTnI expression (as a single cardiac marker by IF or
fluorescence-activated cell sorting [FACS]) to track differ-
entiation status, without also documenting in unison
the complete stoichiometric loss of ssTnI expression. We
propose the following cTnI:ssTnI protein isoform ratio,
quantified by western blot analysis (with a pan TnI isoform
antibody as shown here), be implemented for the develop-
mental stage classification of populations of stem cell-
derived cardiac myocytes: immature = 0:100 to 15:85;
neonatal-like = >15: <85 to 90: 10; mature profile = 100:0
(Figure 6). Other techniques such as IF or FACS would not
be adequate for quantifying this TnI isoform profile
because of limitations in precise ratiometric analysis of
the stoichiometrically conserved cTnI:ssTnI isoform ratio.
Numerous cardiac markers, including molecular, struc-
tural, and physiological, have been used in attempt to track
and classify cardiac cells derived from stem cell progenitors
or from direct reprogramming (Ieda et al., 2010; Qian et al.,
2012). The sarcomere markers cTnT and myosin are in
frequent use, along with the detection of myofilament stri-
ations, myocyte morphology, Ca2+ handling, rhythmic
beating, action potential shape, and others for cardiac line-
age assignment and development assessment (Radisic
et al., 2004; Lundy et al., 2013). Limitations of these
markers include questions of lineage specificity (e.g.,
cTnT is also expressed in smooth muscle) and develop-
mental progression. For example, markers such as TnT
and MyHC show isoform developmental regulation with
the complicating feature of reversion to the ‘‘fetal’’ program
in disease (Parker et al., 1990; Kinugawa et al., 2001). The
failing adult cardiac myocyte reactivates the fetal program
at many levels, including structural, hormonal, and meta-
bolic gene profile by downregulating adult gene transcripts
(Parker et al., 1990; Kinugawa et al., 2001). For instance,
transcript levels of ANF, BNP, skeletal actin, bMHC, and
metabolic genes such as GLUT1 are higher in the human
fetal and failing hearts than in the normal adult heart (Pas-
ternac and Cantin, 1990; Tanaka et al., 1995; Shioi et al.,
2000). In concert, transcript levels of adult genes such asexpression (D) in hiPSC-CMs. cTnC is used as cardiac-specific
loading control and for normalization of samples for quantification
purposes. See also Figure S5. Values are analyzed by one-way
ANOVA with Bonferroni post hoc test and expressed as mean ± SEM,
n = 3 independent experiments, *p < 0.05.
uthors
Figure 6. TNNI Protein Isoform Switch as a Quantitative
Maturation Marker for Stem Cell-Derived Cardiac Myocytes
(A) Schematic of the cardiac sarcomere thin filament illustrating
the stoichiometrically conserved transition from the fetal TnI
(ssTnI) to the adult TnI isoform (cTnI) profile. Owing to strict
protein content control in the sarcomere, the ssTnI isoform must be
removed before the cTnI isoform can occupy the same position in
perfect 1:1 synchrony during development. At any time in devel-
opment, the transition from ssTnI to cTnI is definitive in that it
cannot revert (blocked arrow on right).
(B) Hypothetical western blot based on published work from Sasse
et al. (1993) depicting the TnI isoform profile in cardiac develop-
ment.
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such as GLUT4 are reduced in failing human heart (Paster-
nac and Cantin, 1990; Tanaka et al., 1995; Lowes et al.,
1997; Shioi et al., 2000). Previous studies have used one
or more of these genes to evaluate maturation of in vitro
derived cardiac myocytes (Radisic et al., 2004; Chan et al.,
2013b; Lundy et al., 2013). Therefore, it cannot be certain
by testing, for example, MyHC isoforms or Ca2+ handling
function that the myocytes in question are at a fetal stage
of development or rather are reverting in profile owing to
latent activation of the fetal program. In other words,
markers in frequent use today in cardiac stem cell biology
are highly plastic in nature, making difficult any specific
assignment of myocyte maturation. As mentioned, be-
cause cardiac TnT is also expressed in smooth muscle cells,
the use of cTnT to quantify CMs must be interpreted with
caution. Therefore, it is important to incorporate at least
a second cardiac-specific marker for cardiac lineage assign-
ment. Equally important, the use of MLC2a and MLC2v to
define maturation is not straightforward. This is because
although at early developmental time points most hiPSC-
CMs express MLC2a and not MLC2v, at later time points,
they express robust MLC2v, with MLC2a still significantly
expressed. To be classified as a mature ventricular myocyte,Stem Cellstem cell-derived CMs require 100% cTnI (and 0% ssTnI)
that is colocalized with MLC2v. MLC2v alone cannot serve
as a mature marker in CMs, as we show MLC2V-positive
myocytes express primarily ssTnI (the immature marker)
(Figure S4).
In our long-term cultures of human iPSC CMs, the
cTnI:ssTnI ratio stalled at 2:98, making it fetal-like with
regard to the TnI isoform profile. This stalled marker of
development was observed using different differentiation
protocols, in multiple hiPSC lines (five hiPSC-CMs line ob-
tained from different labs) and over long-term culture (9+
months). In an attempt to modify this ratio via extrinsic
signaling mechanisms, we employed varied media modi-
fications including thyroid hormone supplementation. In
rodent myocytes in culture, T3-supplemented media accel-
erated the transition from ssTnI to cTnI; however, in human
iPSC-CMs, no change in the TnI isoform ratio was obtained.
The basis for the lack of effect of T3 on hiPSC-CMs to influ-
encechanges inTnI isoforms isnot clear. Recent studieshave
shown T3 to have an effect on aMHC and SERCA2a expres-
sion profiles inhiPSC-CMs, indicating that key components
of the T3 signaling cascade are present (Ivashchenko et al.,
2013; Yang et al., 2014). The only successful method used
here to more closely approach the mature adult TnI signa-
turewas via direct gene transfer ofTNNI3, whichwas highly
efficient in stoichiometric replacement of ssTnI with cTnI,
similar in practice to our previous work in adult cardiac
myocytes (Westfall et al., 1997; Day et al., 2006).
Along with implementing TnI isoform ratio as a matu-
ration marker, it is well known that TnI isoforms have sig-
nificant physiological implications for cardiac myocyte
performance (Siedner et al., 2003; Davis et al., 2008). There
is considerable debate regarding identifying the specific
properties of stem cell-derived cardiac myocytes most
suitable in terms of effecting physiologically meaningful
regeneration/repair in disease myocardium in vivo. In
terms of the profile of TnI isoform expression, there are pos-
itive and negatives attributed to the fetal and adult forms of
the TNNI gene. The TNNI1 gene product, ssTnI, has unique
molecular switch properties that would be expected to be
an advantage in terms of survival in the harsh environment
where stem cell-derived myocytes are placed upon transfer
to ischemic and diseased hearts. Here, the ssTnI protein
confers robust Ca2+ activated contraction in an environ-
ment where blood supply is inadequate and in the
biochemical milieu of acidosis (Westfall et al., 1997; Day
et al., 2006), as would be expected during cellular trans-
plantation. A negative aspect of ssTnI function relates to
its detrimental effects on relaxation performance owing
to comparatively slow inactivation of the thin filament
in diastole (Davis et al., 2008). In comparison, the adult
TNNI3 gene product, cTnI, by virtue of its unique
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performance to the myofilaments that is physiologically
important to overall normal heart performance (Davis
et al., 2008). However, a negative attribute of cTnI is its
marked downregulation in function in ischemic/hypoxic
conditions that would be expected in the milieu of the
transplanted myocytes (Westfall et al., 1997; Day et al.,
2006). In this light, the ideal TnI molecule would retain
the best properties of both cTnI and ssTnI isoforms. We
have used structure-function and evolutionary biology
concepts to guide construction of a unique TNNI gene
product that incorporates an acidosis resistant histidine
buttonwhile retaining fast inactivation properties required
to cardiac lusitropy during adrenergic stimulation (Day
et al., 2006). We would propose this engineered molecular
switch protein to be ideal in genetic design of stem cell-
derived cardiac myocytes for repair in vivo.
While the TnI isoform ratio is proposed here to be neces-
sary for tracking maturation of stem cell-derived cardiac
myocyte, it is not sufficient, on its own, to establish
the mature adult cardiac myocyte state. Many other well-
defined physiological and structural markers must also
assemble in concert to fully define a myocyte as adult,
including highly refined Ca2+ handling, exquisite cell
morphology and subcellular structure, and unique physio-
logical forces andmotion. Ultimately, these features, which
are critical but limited by their restricted use in isolation
(owing to issues of fetal-like reversion in stress and disease
states), make the TnI switch profile valuable as an immu-
table barometer to gauge methods seeking to advance
stem cell-derived myocytes toward the mature adult state.
Mindful of the complexities listed above, the cTnI:ssTnI
protein isoform ratio will enable a differentiation status
standard on which cardiac myocytes can be directly
compared between research groups as we have tested in
this study. This could be useful in cardiac stem cellmyocyte
applications in the lab and the clinic.EXPERIMENTAL PROCEDURES
Isolation and Culture of Rodent CMs
Animals used in these experiments were handled in accordance
with guide lines set by the Institutional Animal Care andUse Com-
mittees (IACUC) of University ofMinnesota protocol approval. For
in vitro culture experiments, hearts were obtained from P0-P1
Sprague-Dawley rat pups. Rat neonatal ventricular cardiac myo-
cytes (R-NVCM) were isolated using sequential enzyme digestion
as described in the isolation kit (Worthington). R-NVCMs were
plated either onto poly-D-lysine-coated coverslips or poly-D-
lysine-coated + matrix coverslips for 1–2 hr. Medium was changed
every 2–3 days. A similar protocol was used for the isolation and
in vitro culture of mouse neonatal ventricular cardiac myocytes
(M-NVCM).602 Stem Cell Reports j Vol. 3 j 594–605 j October 14, 2014 j ª2014 The AIsolation of Hearts from Rodent Pups
For in vivo developmental study, hearts from pups were isolated at
different developmental time points: P1, P3, P5, P7, P10, P15, and
P20. Protein or RNAwas isolated from each hearts at different time
points indicated and used for western blotting, mRNA expression,
and immunohistochemistry. Animals used in these experiments
were handled in accordance with guideline set by the IACUC of
University of Minnesota protocol approval.
Maintenance of hiPSCs and Differentiation into
Cardiac Myocytes
The primary hiPSC line used in this study was DF 19-9-11 (derived
from neonatal skin fibroblast) and was maintained on feeder-free
Matrigel (BD Biosciences) in mTeSR1 or TeSR-E8 medium (STEM
CELL Technologies) (Figure S1A). For cardiac differentiation via
small molecules, as adapted from Lian et al. (2012), hiPSCs were
maintained on Matrigel plates for 4 days or until they reached
confluence. Cells were treated with 10 mM CHIR99021 (GSK-3 in-
hibitor, Selleck Bio) alongwithMatrigel in RPMI/B27without insu-
lin (Invitrogen) for 24 hr (day 0 to day 1). The next day, medium
was changed to RPMI/B27 without insulin plus inhibitor of Wnt
protein 4 (IWP4) at 5 mM (Stemgent) and removed during the me-
dium change on day 2. Cells were maintained in the RPMI/B27
plus insulin starting from day 7, with media changes every 1–
2 days (Figures S1A and S1B). The use of RPMI and B27+ insulin
cocktail culture condition has the advantage of preventing fibro-
blast overgrowth compared to use of FBS. Regular media changes
were performed to limit pH alterations.
HiPSC-CMs Using Different Lines and Differentiation
Protocols
Line 1 hiPSCs (DF19-9-11 hiPSCs) (derived from [neonatal] skin fi-
broblasts) were maintained in culture for 4–5 days onMatrigel (BD
Biosciences) and mTeSR medium (STEMCELL Technologies). Dif-
ferentiation was initiated as described previously (Zhang et al.,
2012) by adding cold RPMI/B27minus insulin containingMatrigel
(0.5mg/plate) and 100 ng/ml Activin A (R&D Systems) at day 0. At
day 1, medium was exchanged with RPMI/B27 minus insulin sup-
plement containing 5 ng/ml BMP4 (R&D Systems) + 5 ng/ml bFGF
(Invitrogen) until day 5. Starting at day 5, differentiating hiPSCs
were fed with medium containing RPMI/B27 complete supple-
ment (+ insulin) at interval of 2–3 days. Protein and RNA samples
were collected at day 15 postinitiation of beating.
Lines 2 and 3 hiPSCs (IPLZ3.13 and IBO5.57 hiPSC) (derived
from skin fibroblasts) were maintained in culture for 4–5 days on
Matrigel (BD Biosciences) and mTeSR medium (STEMCELL Tech-
nologies). Differentiation was initiated as described previously
(Zhang et al., 2012) by adding cold RPMI/B27 minus insulin (Invi-
trogen) containing Matrigel (0.5 mg/plate) and 100 ng/ml Activin
A (R&D Systems) and 10 mMCHIR-99021 (Selleck Bio) at day 0. At
day 1, medium was exchanged with RPMI/B27 minus insulin sup-
plement containing 5 ng/ml BMP4 + 5 ng/ml bFGF (R&D Systems).
At day 3, IWP4 (Stemgent) was supplemented at final concentra-
tion of 5 mM. Starting at day 5, differentiating hiPSCs were fed
withmedium containing RPMI/B27 complete supplement (+ insu-
lin) at interval of 2–3 days. Protein and RNA sampleswere collected
at day 30, 3 months, and 5 months.uthors
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maintained in culture for 4–5 days on Matrigel and mTeSR me-
dium.Differentiationwas initiated intoCMs via theMatrigel sand-
wich method, as described previously (Zhang et al., 2012). Briefly,
13 106 single hiPSCs were expanded on aMatrigel-coated dish for
3–5 days, and then differentiation was induced on day 0 by
culturing the cells with 100 ng/ml Activin A (R&D Systems) in
RPMI basal medium plus B27 without insulin. Twenty-four hours
later (i.e., on day 1 of differentiation), cells were treated with
10 ng/ml BMP4 and 7.5 ng/ml bFGF (R&D Systems) in RPMI basal
medium plus B27 without insulin. Four days later (i.e., on day 5 of
differentiation), cells were cultured in RPMI basal medium with
normal B27, and beating cells usually appeared approximately
on day 8 after differentiation was initiated. Protein and RNA sam-
ples were collected at day 10, day 30, and day 80.
Line 5 hiPSCs (13FLVN0C1 hiPSCs) (derived from skin fibro-
blasts) were maintained in culture for 5 days on Matrigel (BD Bio-
sciences) and TeSR-E8 medium. Differentiation was initiated as
described previously (Lian et al., 2012) by adding 12 mM CHIR-
99021 with RPMI/B27 minus insulin supplement at day 0. At day
3, IWP2 was added at final concentration of 5 mM. At day 7, differ-
entiating hiPSCs were fed with medium containing RPMI/B27
complete supplement (+ insulin) at interval of 2–3 days. Protein
and RNA samples were collected at 1 month after initiation of
beating.
Generation of Inducible Mesp1-mESC and Their
Differentiation into Cardiac Myocytes
mESC-derived cardiac myocytes were obtained using a doxycy-
cline-inducible Mesp1 mESC line (Chan et al., 2013a). For cardiac
differentiation, embryoid bodies (EBs) were aggregated by seeding
0.5million single cells per 10ml in a petri dishwith orbital shaking
(70 rpm) (day 0) (Figure S1C). Media changes were on days 3 and 4.
Doxycycline was added on day 3 at a final concentration of
500 ng/ml and removed on day 4. IWR1 was added on day 3 at a
final concentration of 10 mM. EB cells were harvested on day 6.
Beating EBs were dissociated using trypsin to obtain single cardiac
myocytes. Trypsinized individualized cardiac myocytes were
seeded on coverslips coated with either poly-D-lysine or poly-D-
lysine plus cardiac matrix at cell density of 150–200,000 cells per
coverslip.
T3 Supplementation in Culture of hiPSC-CMs and
Rodent CMs
The possible direct effect of T3 (Sigma) on the TNNI isoform
switching was tested by supplementing T3 (10 nM) for 2 weeks
in cultures of 2 months postbeating hiPSC-CMs and at early
time points shortly after the onset of beating (day 1 postbeat
hiPSC-CMs). Similarly, day 1 Mesp1-mESC-CM, M-NVCM, and
R-NVCM were supplemented with T3 for 2 weeks. The expression
of cTnI was assessed by western blotting on protein samples
collected 15 days after treatment.
Transduction of hiPSC-CMs or Rodent CMs with
Adenoviral Vectors
HiPSC-CMs or rodent-CMs were transduced with recombinant
adenovirus vectors harboring cTnI(C-terminal flag tagged) inStem Cellserum-free medium for 2–3 hr at multiplicity of infection of 100–
200. The transduced hiPSC-CMs were maintained in culture with
RPMI supplemented with B27 plus insulin.
Western Blotting and Indirect Immunohistochemistry
Cardiac myocytes were lysed in RIPA buffer containing protease
and phosphatase inhibitor mixture. Proteins were separated by
10% (wt/vol)TrisGlycine SDS/PAGE (Invitrogen) under denaturing
conditions and transferred to a nitrocellulose membrane. After
blocking with 5% milk Tris-buffered saline Tween-20 (TBST) for
1 hr, the membrane was incubated with primary antibody over-
night at 4C. The membrane was washed, incubated with an
anti-mouse/rabbit fluorescent dye-conjugated secondary antibody
(1:5,000, Invitrogen) at room temperature for 1 hr and scanned by
Odyssey (Bio-Rad). Primary antibodies used includedmouse raised
pan-TnI specific (MAB1691), cTnC, MLC2a and rabbit raised TnT,
MLC2v. Blocked samples were probed with pan TnI specific
(MAB1691), cTnC (1A2), cTnI (4C2), andMLC2aprimary antibody
each raised in mouse (1:1,000 dilution) or TnT, ssTnI, and MLC2v
primary antibody each raised in rabbit (1:1,000 dilution). cTnC
raised in mouse (clone 1A2 Abcam) was used to evaluate protein
loading. The binding of primary antibodies was detected by goat
anti-rabbit (IRDye 800 conjugates) (Rockland Immunochemicals)
or goat anti-mouse (Alexa Fluor 680 conjugates) (Invitrogen) sec-
ondary antibodies (1:5,000) and scanned with LI-COR Odyssey
infrared imaging system (LI-COR Biosciences).
For indirect immunohistochemistry, hiPSC-CMs were fixed in
4% paraformaldehyde for 5–10 min at room temperature and per-
meabilized with 0.25% Triton X-100 in PBS. Permeabilized cells
were blockedwith 20% goat serum. Blockedmyocyteswere probed
with primary antibodies specific for anti-myosin light chain
MLC2a (1:1,000, Synaptic Systems), cTnI (4C2) and sarcomeric ac-
tinin (EA-53) raised in mouse (1:1,000, Sigma), and MLC2v, ssTnI,
and TnT raised in rabbit (1:1,000 dilution). The binding of primary
antibodies was visualized with goat anti-mouse immunoglobulin
G conjugated to Alexa 488 (1:1,000, Sigma) and goat anti-rabbit
conjugated to Alexa Fluor 594 secondary antibodies (1:1,000).
Representative cells were photographed using a Zeiss confocal
microscope.
Statistical Analysis
Data are expressed asmean± SEMwith Student’s t test to determine
statistical significance. For comparison among three or more treat-
ment groups, one-way ANOVA was used. For comparison among
treatment groups with two independent variables, two-way
ANOVA was used. p < 0.05 was considered statistically significant.
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